Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (2): 353-359    DOI: 10.31083/j.ejgo.2021.02.5419
Original Research Previous articles | Next articles
miR-182-5p enhances cisplatin resistance in epithelial ovarian cancer by downregulating GRB2
Chun-Yu Zhang1, Chun-Yan Chen1, Hai-Xia Wen1, Zi-Feng Song1, Ping-Ping Hu1, *()
1Department of Obstetrics, Zhejiang University Mingzhou Hospital, 315000 Ningbo, Zhejiang, China
Download:  PDF(642KB)  ( 108 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Epithelial ovarian cancer (EOC) patients often experience cisplatin resistance. This study analysed the miR-182 level in EOC patients, and explored the association between miR-182 with chemoresistance in EOC. Methods: Using qRT-PCR, the miR-182-5p levels in EOC were determined. miR-182-5p and its associations with the clinicopathological characteristics and overall survival of EOC patients were analysed. A2780/DDP cells and A2780 cells were transfected with miR-182-5p mimics or inhibitor. Then, using a CCK8 assay, cell viabilities were assessed. To determine if GRB2 is a bona fide miR-182-5p target, a dual luciferase reporter assay was carried out. Then, the cell viability in A2780/DDP cells overexpressing GRB2 was determined. Results: Compared with adjacent normal tissues, the miR-182-5p was significantly upregulated in EOC tissues. High levels of miR-182-5p were associated with frequent platinum resistance and poor overall survival in EOC patients. Upregulation of miR-182-5p by its mimics significantly enhanced the cisplatin resistance of A2780 cells. Conversely, miR-182-5p inhibitors significantly enhanced the cisplatin sensitivity of A2780/DDP cells. GRB2 was confirmed as a bona fide miR-182-5p target in EOC. In GRB2-overexpressing EOC cells, cisplatin sensitivity was significantly enhanced. Conclusions: miR-182-5p enhanced the cisplatin resistance of EOC cells by downregulating GRB2, which is a novel target for predicting the prognosis and improving the treatment of EOC.
Key words:  Epithelial ovarian cancer      miR-182      GRB2      Cisplatin      Chemoresistance     
Submitted:  22 October 2019      Revised:  13 May 2020      Accepted:  13 May 2020      Published:  15 April 2021     
*Corresponding Author(s):  Ping-Ping Hu     E-mail:  h464071@163.com

Cite this article: 

Chun-Yu Zhang, Chun-Yan Chen, Hai-Xia Wen, Zi-Feng Song, Ping-Ping Hu. miR-182-5p enhances cisplatin resistance in epithelial ovarian cancer by downregulating GRB2. European Journal of Gynaecological Oncology, 2021, 42(2): 353-359.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.02.5419     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I2/353

[1] Yumiko Goto, Yoshie Kametani, Aurélie Auguste, Thuraya Almamari, Audrey LeFormal, Shun-ichiro Izumi, Catherine Genestie, Hitoshi Ishimoto, Mikio Mikami, Alexandra Leary. Tropomyosin-related kinase B (TrkB) full-length isoform is related to advanced-stage clear cell ovarian cancer (CCOC)[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 899-908.
[2] Diane E. Mahoney, Shariska Petersen, Lori Spoozak, Brenda M. Linares, Janet D. Pierce. The role of microbiota in epithelial ovarian cancer: a scoping review[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1006-1017.
[3] Paul H. Sugarbaker. Eliminating tumor cell entrapment from the natural history of ovarian cancer, a narrative summary[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 615-620.
[4] Ana Carolinne da Silva, Millena Prata Jammal, Renata Margarida Etchebehere, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini. Association of cancer-associated fibroblasts and survival in malignant ovarian neoplasms[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 782-787.
[5] Mehmet Sait Bakır, Özer Birge, Ceyda Karadag, Selen Doğan, Hasan Aykut Tuncer, Tayup Simsek. Clinicopathological risk factors and survival analysis of ovarian cancer with synchronous endometrial cancer diagnosed after surgery[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 499-505.
[6] Meng-Hui Huang, Yun Han, Qing-Hua Xi, Yun-Feng Jin, Ying-Lei Liu, Yu-Wen Han, Hai-Li Kai, Qian Zhang, Yan-Li Zheng. Exploration on correlation of high DLX2 expression with poor prognosis and cellular proliferation in epithelial ovarian cancers[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 521-529.
[7] Ece Gumusoglu, Tuba Gunel, Mohammad Kazem Hosseini, Nogayhan Seymen, Taylan Senol, Uğur Sezerman, Samet Topuz, Kılıç Aydınlı. The importance of dysregulated miRNAs on ovarian cysts and epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 66-72.
[8] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[9] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[10] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[11] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[12] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[13] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[14] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[15] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
No Suggested Reading articles found!